Abeona Therapeutics (ABEO) announced the appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug development experience where, in various roles, he oversaw the approval of 15 new treatments that addressed unmet needs in serious diseases with few to no treatment options. Dr. Crombez currently serves as Chief Medical Officer of Ultragenyx Pharmaceutical (RARE) and brings extensive expertise in the development and execution of clinical development programs for rare genetic disorders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
- Abeona Therapeutics announces favorable medicare reimbursement decisions
- Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
- Abeona’s Type A meeting with FDA done, BLA resubmission on track, says Stifel
- Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission